$PHVS

Lesage Anne sold $81K of PHVS (indirect holdings)

Lesage Anne (Chief Early Development) sold 2,300 indirectly-held shares of Pharvaris N.V. (PHVS) at $35.12 on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lesage Anne
Published Jun 29, 2026, 10:41 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 29, 2026, 10:45 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PHVS
Neutral
high confidence
Mentioned
$PHVS
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (2,300 shares at $35.1242) and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

This provides incremental transparency on insider activity but does not introduce new fundamentals, guidance, or regulatory/clinical catalysts.

03

What to watch

Indirect holdings and 10b5-1 structure can obscure true discretion; the modest size ($80.8K) limits interpretive power versus larger, non-10b5-1 transactions.

Relevance 2/10Novelty 3/10Timing: Filed 2026-06-29; sale executed 2026-06-25

Background

The article is an SEC Form 4 insider transaction disclosure for Pharvaris N.V. (PHVS).

Company-level read

Ticker impact

$PHVSNeutralHigh confidence
Context

SEC Form 4 shows officer Lesage Anne sold 2,300 PHVS shares on 2026-06-25 under a 10b5-1 plan, totaling ~$80.8K.

Expected impact

Low likelihood of sustained price impact; any reaction should be muted unless accompanied by other company-specific catalysts.

Evidence & confidence

The filing is a disclosed open-market sale with a pre-arranged 10b5-1 plan and modest dollar value, which typically reduces interpretive weight versus discretionary selling.

Market effects

No sector read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with periods of reduced conviction; traders may still monitor for a pattern across filings.

Key entities

  • PHVS

    Pharvaris N.V., the company whose insider transaction is disclosed.

  • Lesage Anne

    Chief Early Development; reported an open-market sale of PHVS shares via indirect holdings.

Related articles

MedAI 8/10

Pharvaris Gains FDA Acceptance For Deucrictibant In Hereditary Angioedema

Pharvaris N.V. (PVHS) said the U.S. FDA accepted its NDA for deucrictibant immediate-release 20 mg capsules for on-demand treatment of hereditary angioedema attacks. A PDUFA action date is April 23, 2027. The submission cites Phase 3 RAPIDe-3 results (median onset 1.28 hours; complete resolution 11.95 hours; >1,300 attacks; primary and 11 secondary endpoints met).